ÆÊÎö¿ÆÑ§½çÒÑÖªµÄÂѰ׽ṹÐèÒª¶à¾Ã£¿£¿£¿£¿£¿ÒÑÍùµÄÃÕµ×ÊÇ£º30ÍòÄê¡£¡£¡£¡£¡£¡£¡£
ÉÏÊÀ¼Í60ÄêÔÂÖÁ½ñ£¬£¬£¬£¬£¬£¬£¬£¬¿ÆÑ§¼ÒÒÑÆÊÎöÁè¼Ý18Íò¸öÂѰ×ÖÊÈýά½á¹¹£»£»£»£»£»µ«ÏÖÔÚÈËÀàÒÑÖªµÄÂѰ×ÐòÁÐÁè¼ÝÒ»ÒÚ£¬£¬£¬£¬£¬£¬£¬£¬ÒªÊµÏÖ×îÖÕÆÊÎöÄ¿µÄ£¬£¬£¬£¬£¬£¬£¬£¬»¹ÐèÒªºã¾Ã²»Ð¸µÄÆð¾¢¡£¡£¡£¡£¡£¡£¡£¿ËÈÕ£¬£¬£¬£¬£¬£¬£¬£¬AlphaFold2Êý¾Ý¿âÒ»¾ÙÐû²¼Áè¼Ý35ÍòÖÖÂѰ׽ṹÊý¾Ý£¬£¬£¬£¬£¬£¬£¬£¬²¢ÓÐÍûÔÚÊýÔÂÄÚÕ¹ÍûËùÓÐÒÑÖªµÄÂѰ׷Ö×ӽṹ¡£¡£¡£¡£¡£¡£¡£
ÇÒ²»ËµAIÂѰ׽ṹչÍûµÄÓÐÓÃÐÔºÍÍêÕûÐÔ£¬£¬£¬£¬£¬£¬£¬£¬½á¹¹ÉúÎïѧÉÐÓÐÄÄЩӲºËÑо¿µÄÍ»ÆÆ¿Õ¼ä£¿£¿£¿£¿£¿¹ØÓÚ¹¤Òµ½ç¶øÑÔ£¬£¬£¬£¬£¬£¬£¬£¬ÓÖÔõÑùÍŽá¼áʵµÄÑз¢Æ½Ì¨ºÍÇ°ÑØµÄ¿Æ¼¼ÊֶΣ¬£¬£¬£¬£¬£¬£¬£¬»ùÓÚ°ÐÂѰ׽ṹÆÊÎöºÍÒ©Îï-°Ðµã¶¯Ì¬¹¹Ð§ÆÊÎöÍÆ½øÐÂÒ©¿ª·¢£¿£¿£¿£¿£¿ÔÚSDDAµÚ27ÆÚÂÛ̳ÉÏ£¬£¬£¬£¬£¬£¬£¬£¬À´×ÔѧÊõ½çºÍ¹¤Òµ½çµÄר¼Ò̽ÌÖÁË»ù´¡Ñо¿Óë¿ç½ç¿Æ¼¼µÄÉú³¤ÓëÈÚºÏÆ«Ïò¡£¡£¡£¡£¡£¡£¡£
̽Ë÷GPCRÍøÂçÐþÃ£¬£¬£¬£¬£¬£¬£¬Í¸ÊÓ×î´óÒ©°Ð¼Ò×å
GPCR£¨G protein-coupled receptors£¬£¬£¬£¬£¬£¬£¬£¬GÂѰ׿ÁªÊÜÌ壩ÂѰ׼Ò×壬£¬£¬£¬£¬£¬£¬£¬ÊÇ¿ÆÑ§¼Ò×îΪ¹Ø×¢µÄÒ©°Ð±¦²ØÖ®Ò»¡£¡£¡£¡£¡£¡£¡£Áè¼Ý800ÖÖ GPCRÂѰ׹¦Ð§Ó°Ïì×ÅÐÄѪ¹Ü¼²²¡¡¢ÖÐÊàÉñ¾ÏµÍ³¼²²¡¡¢´úлÐÔ¼²²¡¡¢°©Ö¢µÈ¶àÖÖ¼²²¡µÄ±¬·¢Éú³¤¡£¡£¡£¡£¡£¡£¡£Æù½ñÔ¼40%µÄÉÏÊÐÒ©Îï½ÔÒԸüÒ×åÊÜÌåΪ°Ðµã£¬£¬£¬£¬£¬£¬£¬£¬µ«ÏÖÔÚÈÔÓÐÊý°ÙÖÖGPCRÂѰ×ÊÇÐÂÒ©¿ª·¢µÄ¿ÕȱµØ´ø¡£¡£¡£¡£¡£¡£¡£
ÖØ´óµÄGPCR¼Ò×åÔ̲Ø×ÅÄÄЩÐþÃ£¿£¿£¿£¿ÔÚÂÛ̳ÖУ¬£¬£¬£¬£¬£¬£¬£¬À´×ÔÉϺ£¿£¿£¿£¿£¿Æ¼¼´óѧµÄÁõÖ¾½Ü½ÌÊÚΪ¸÷ÈË̸µ½¾Û½¹ÓÚ¸ÃÁìÓòÊ®ÓàÄêµÄÑо¿ÈÏÖª£º¡°ÊôÓÚĤÂѰ׵ÄGPCRÓÉÓÚ±í´ïÁ¿µÍ¡¢¹¹ÏóÖØ´ó¶à±ä£¬£¬£¬£¬£¬£¬£¬£¬Æä´¿»¯ÊÂÇéºÍÈ«½á¹¹ÆÊÎöÌôÕ½ÖØ´ó¡£¡£¡£¡£¡£¡£¡£¡±¶øÑо¿GPCR¸ü¾ßÌôÕ½µÄ£¬£¬£¬£¬£¬£¬£¬£¬ÊÇÃ÷È·Æä¶àÖÖ¹¦Ð§×´Ì¬µÄµ÷¿Ø»úÖÆÒÔ¼°ÏÂÓεÄË«Ïò¡°ÒõÑô¡±Í¨Â·£ºGPCR¿ÉÒÔÌåÏÖΪʧ»î¡¢À༤»î¡¢È«¼¤»îµÈ¶àÖÖ¹¦Ð§×´Ì¬£»£»£»£»£»±»³Æ×÷Æß´Î¿çĤÊÜÌåµÄGPCR£¬£¬£¬£¬£¬£¬£¬£¬¼È¿ÉÒÔ¼¤»îGÂѰ×ÐźÅͨ·£¨Ä¿½ñÈÔÊÇÖ÷Á÷Ñо¿Æ«Ïò£©£¬£¬£¬£¬£¬£¬£¬£¬Ò²¿ÉÒÔÍŽáArrestinÂѰײ¢Òý·¢GPCRÍÑÃô¡¢ÄÚ»¯¡¢¸´Ãô¡¢Ï¸°ûÔöÖ³ºÍ»ùÒòת¼¡£¡£¡£¡£¡£¡£¡£
¡°¾ÓɶàÄê»ù´¡Ñо¿£¬£¬£¬£¬£¬£¬£¬£¬ÈËÃÇÖð½¥½Ò¿ªÁËGPCRµ÷¿ØºÍÐźÅתµ¼µÄÉñÃØÃæÉ´¡£¡£¡£¡£¡£¡£¡£Í¨Ì«¹ýÎö²î±ð¹¦Ð§×´Ì¬µÄÈýά½á¹¹¡¢¹¹Ïóת±ä¡¢ÅäÌåÍŽáλµãºÍÏìÓ¦ÉúÎïÎïÀíÌØÕ÷£¬£¬£¬£¬£¬£¬£¬£¬²»µ«¿ÉÒÔÖ§³ÖÐÂÒ©Ñз¢Ö°Ô±Éè¼Æ¹Å°åµÄ¼¤¶¯¼Á¡¢Þ׿¹¼Á¡¢·´Ïò¼¤¶¯¼ÁµÈÕý¹¹Ò©Î£»£»£»£»Ò²½«Îª¿ÆÑ§½çÌṩÐÂ˼Ð÷£¬£¬£¬£¬£¬£¬£¬£¬¿ª·¢Ñ¡ÔñÐÔ¸üºÃµÄ±ð¹¹Ò©Îï¡¢ArrestinÂÑ°×Æ«ÏòÐÔÒ©Îbiased ligand£©£¬£¬£¬£¬£¬£¬£¬£¬ÒÔ¼°¿Éͬʱ×÷ÓÃÓÚÕýλºÍ±ä¹¹Î»µãµÄ¶à¼ÛÅäÌ壨dualsteric/multivalent ligand£©¡£¡£¡£¡£¡£¡£¡£¡±
Áõ½ÌÊÚÌåÏÖ£¬£¬£¬£¬£¬£¬£¬£¬ÏÖÔÚAIϵͳ¿É»ùÓÚÈËÀàÒÑÖªÊÖÒÕ¾ÙÐÐÉî¶ÈѧϰºÍÅÌË㣬£¬£¬£¬£¬£¬£¬£¬Ê¹ÂѰ×ÖÊ·Ö×ÓµÄÈýά½á¹¹Õ¹Íû¾«¶Èǰ½øÁËÒ»´ó²½£¬£¬£¬£¬£¬£¬£¬£¬µ«ÏÖÔÚ»¹È±·¦ÓëÒ©ÎïÑз¢Ç×½üÏà¹ØµÄ°±»ùËá²àÁ´¡¢ÅäÌåÓëÂѰ׷Ö×ÓÏ໥×÷ÓõÄÒªº¦ÐÅÏ¢¡£¡£¡£¡£¡£¡£¡£¡°ÈôÊÇAIϵͳҪʵÏÖ¶ÔÉÏÊöÌØÕ÷ÒÔ¼°ÂѰ×Öʶ¯Ì¬ÐÔ×ÓµÄÖÜȫչÍû£¬£¬£¬£¬£¬£¬£¬£¬¿ÉÄÜÐèҪʹÓÃÁ¿×ÓÅÌËã»úµÄ·Ö×Ó¶¯Á¦Ñ§¹¤¾ß£¬£¬£¬£¬£¬£¬£¬£¬´ÓµÚÒ»ÐÔÔÀí½Ç¶È¿¼²ì²î±ð¹¦Ð§×´Ì¬µÄGPCRÊôÐÔ£¬£¬£¬£¬£¬£¬£¬£¬ÎÒÃÇÆÚ´ýδÀ´¿´µ½AI+Á¿×ÓÅÌËã¿Æ¼¼µÄÉú³¤ÐÂÆ«Ïò¡£¡£¡£¡£¡£¡£¡£¡±
¾Û½¹¶¯Ì¬¹¹Ð§ÆÊÎö£¬£¬£¬£¬£¬£¬£¬£¬²Î͸ҩÀí»úÖÆÄѵã
×÷Ϊҵ½çÁìÏȵĽṹÉúÎïѧƽ̨ÈÏÕæÈË£¬£¬£¬£¬£¬£¬£¬£¬°Û°¿µÃ×Ü˾ÀíÎâ¼ÒȨ²©Ê¿ÔÚÑݽ²ÖÐÌåÏÖ£¬£¬£¬£¬£¬£¬£¬£¬ÃæÁÙÈ«Çò¹¤Òµ½çÇ¿ÁҵľºÕùÃûÌ㬣¬£¬£¬£¬£¬£¬£¬º£ÄÚÆóÒµÔÚ²úÆ·ÏßÁ¢ÏîʱһֱÏòÔ´Í·Á¢Òì̽Ë÷£¬£¬£¬£¬£¬£¬£¬£¬²¢Ôڰе㡢»úÖÆ¡¢ÖƼÁ²ãÃæ·ºÆð²»ÉÙÁ¢ÒìÁÁµã£¬£¬£¬£¬£¬£¬£¬£¬¶ø»ùÓڰеã½á¹¹ºÍÉúÎï»úÀíÑо¿µÄÒ©Î↑·¢ÈÔÊÇÐÂÒ©Ñз¢µÄÆðµãºÍÖ÷Á÷Æ«Ïò¡£¡£¡£¡£¡£¡£¡£
°Û°¿µÃ½üÆÚͨ¹ýÒ©Îï-°Ðµã¹¹Ð§¹ØÏµÆÊÎö£¬£¬£¬£¬£¬£¬£¬£¬ÀÖ³ÉÚ¹ÊÍÁËÒ»¿î¿¹Ð¹ڲ¡¶¾ÁÙ´²ÐÂÒ©µÄÒ©Àí»úÖÆ¡£¡£¡£¡£¡£¡£¡£Îâ¼ÒȨ²©Ê¿ÌåÏÖ£º¡°ÖÁ½ñ°ÐÏòйڲ¡¶¾µÄÌØÒìÐÔÒ©ÎïÈÔȻȱ룬£¬£¬£¬£¬£¬£¬£¬Ô±¾ÓÃÓÚÖÎÁư£²©À²¡¶¾µÄÈðµÂÎ÷Τ£¨Remdesivir£©ºÍÖÎÁÆÁ÷¸ÐµÄ·¨Æ¥ÀΤ£¨Favipiravir£©£¬£¬£¬£¬£¬£¬£¬£¬ÒÑÔÚÈ«Çò²»ÉÙµØÇøÓÃÓÚÓ¦¶ÔÒßÇé¡£¡£¡£¡£¡£¡£¡£ÎÒÃÇÕë¶Ô¾³Íâ¿Í»§¿ª·¢µÄÒ»ÖÖRdRP£¨RNA-dependent RNA polymerase, RNAÒÀÀµÊ½RNA¾ÛºÏø£©ÒÖÖÆ¼Á£¬£¬£¬£¬£¬£¬£¬£¬ÔÚ60ÌìÄÚÍê³ÉÆä»úÀíÑо¿£¬£¬£¬£¬£¬£¬£¬£¬²¢Í¨¹ýÆÊÎöRdRPºÍС·Ö×ÓÒ©ÎïµÄÀä¶³µç¾µ½á¹¹£¬£¬£¬£¬£¬£¬£¬£¬·¢Ã÷¸ÃÒ©Îï·Ö×Ó²»µ«¿ÉÒÔ¹²¼ÛÐÞÊÎRNAµ×Î£¬£¬£¬£¬£¬£¬£¬»¹¿ÉÒÔÍŽáÆäËüλµãÒÖÖÆRdRPÂѰ×NSP8µÄ¼¤»î°ì·¨£¬£¬£¬£¬£¬£¬£¬£¬´Ó¶øÒÖÖÆÏÂÓÎRNA¸´ÖÆÐźÅͨ·Æô¶¯¡£¡£¡£¡£¡£¡£¡£¸ÃÒ©Îï°ÐÏòйڲ¡¶¾µÄ¸ßÑ¡ÔñÐÔÓÐÍûÁè¼ÝÈðµÂÎ÷Τ¡¢·¨Æ¥ÀΤÊý±¶¡£¡£¡£¡£¡£¡£¡£¡±
ÁõÖ¾½Ü½ÌÊÚÍŶÓÔÚÑо¿´óÂéËØÊÜÌ壨cannabinoid receptor£¬£¬£¬£¬£¬£¬£¬£¬CB£©½á¹¹µÄͬʱ£¬£¬£¬£¬£¬£¬£¬£¬Ò²ÔÚ¶¯Ì¬¹¹Ð§²ãÃæÆÊÎöÁ˸üÒ×åÂѰ×Óë¶àÖÖÓгÉҩDZÁ¦Ð¡·Ö×ӵĸ´ºÏÎï¡£¡£¡£¡£¡£¡£¡£´óÂéÖеÄÖ»óɷݡª¡ªËÄÇâ´óÂé·Ó£¨THC£©Ö÷Òª×÷ÓÃÓÚÈËÌåÄÚÔ´ÐÔ´óÂéËØÊÜÌåCB1¡¢CB2£¬£¬£¬£¬£¬£¬£¬£¬Á½ÕߵĶàÖÖÅäÌ壨¼¤¶¯¼Á¡¢Þ׿¹¼Á£©¿ÉÓÃÓÚÖÎÁÆÌÛÍ´¡¢Ñ×Ö¢¡¢Éñ¾ÍËÐÐÐÔ¼²²¡¡¢·ÊÅÖÖ¢ÒÔ¼°¸ÎÏËά»¯µÈ¼²²¡¡£¡£¡£¡£¡£¡£¡£
ÆäÖУ¬£¬£¬£¬£¬£¬£¬£¬CB1ΪÖÐÊàÉñ¾ÏµÍ³ÂþÑÜ×îΪÆÕ±éµÄGPCRÂѰ×Ö®Ò»£¬£¬£¬£¬£¬£¬£¬£¬Óë»ùÓÚTHC¿ª·¢µÄ¶àÖÖ¼¤¶¯¼ÁС·Ö×ÓÍŽáºó£¬£¬£¬£¬£¬£¬£¬£¬»á±¬·¢Ç¿ÁҵĹ¹Ïóת±ä£¬£¬£¬£¬£¬£¬£¬£¬ÇÒÁ½¸ö°±»ùËáλµã»á±¬·¢Ðͬ¹¹Ïóת±ä£¨twin toggle switch£©¡£¡£¡£¡£¡£¡£¡£¡°ÓÉ´ËÎÒÃÇ´Ó·Ö×ÓˮƽڹÊÍÁËTHCΪºÎÖÂñ«ÐÔ½ÏÈõ¡£¡£¡£¡£¡£¡£¡£ÁíÍâÒ»¸öÓÐȤµÄ·¢Ã÷£¬£¬£¬£¬£¬£¬£¬£¬ÊÇCB1¡¢CB2ÓëÞ׿¹¼Á»®·ÖÍŽáºó¹¹Ïó·´²îºÜ´ó£»£»£»£»£»CB1Ó뼤»î¼ÁÍŽᡢCB2ÓëÞ׿¹¼Á¼°¼¤¶¯¼ÁÍŽáµÄÈýÀิºÏÎï½á¹¹¸ß¶ÈÏàËÆ¡£¡£¡£¡£¡£¡£¡£Á½ÖÖ´óÂéËØÊÜÌåµÄ½á¹¹Ñо¿£¬£¬£¬£¬£¬£¬£¬£¬½«¶ÔËüÃÇÔÚÖÐÊàÉñ¾ÏµÍ³ºÍÃâÒßϵͳÖл®·ÖʩչµÄ¹¦Ð§Ñо¿¡¢ÒÔ¼°Î´À´Ïà¹ØÐÂÒ©¿ª·¢ÌṩÖ÷Òª²Î¿¼¡£¡£¡£¡£¡£¡£¡£¡±
¹Å°åÑо¿Ð¯ÊÖAI¿Æ¼¼£¬£¬£¬£¬£¬£¬£¬£¬Íƶ¯ÐÂÒ©¿ª·¢Ç°½ø
½üÆÚAlphaFold2Õë¶ÔÈËÀàºÍ¶àÖÖģʽ¶¯Îϸ°ûµÄ¾²Ì¬ÂѰ×Èýά½á¹¹×ö³öÁ˾«×¼Õ¹Íû£¬£¬£¬£¬£¬£¬£¬£¬ÓпÆÑ§¼ÒÒÔΪ¸ÃЧ¹ûÊÇÈËÀà»ùÒò×é²âÐòÍê³ÉÖ®ºóµÄÓÖÒ»ÖØ´óÉúÃü¿ÆÑ§Í»ÆÆ¡£¡£¡£¡£¡£¡£¡£ÁõÖ¾½Ü½ÌÊÚÌåÏÖ£º¡°ÏÖÔÚAIÊý¾Ý¿âÕ¹ÍûµÄÊÇÂѰ×ÔÚÎȹ̡¢µÍÄÜÁ¿×´Ì¬ÏµÄÈýά½á¹¹£¬£¬£¬£¬£¬£¬£¬£¬Ò©Î↑·¢ÔòÐèÒªÖØµãÑо¿¼¤»î̬¡¢¸ßÄÜÁ¿×´Ì¬ÏµÄÂѰ׽ṹºÍÊôÐÔ£¬£¬£¬£¬£¬£¬£¬£¬²¢ÒÔ´ËΪÆðµãÆÊÎöÔ×ÓˮƽµÄÂѰ×-ÂѰ×Ï໥×÷Óá¢ÂѰ×-ÅäÌ帴ºÏÎï½á¹¹¡£¡£¡£¡£¡£¡£¡£»£»£»£»£»úеѧϰµÄЧ¹û¹ØÓÚÎÒÃǵĻù´¡Ñо¿ÓÐÖ÷Òª²Î¿¼¼ÛÖµ£¬£¬£¬£¬£¬£¬£¬£¬ÎÒÃÇδÀ´»¹ÐèҪ̽Ë÷¸ü¶àµÄÂѰ×-ÅäÌ嶯̬¹¹Ð§¹ØÏµÒÔ¼°ÂѰ×DZÔÚ³ÉÒ©ÍŽáλµãÐÅÏ¢¡£¡£¡£¡£¡£¡£¡£¡°
ÔÚ»ù´¡¿ÆÑ§Ö®Í⣬£¬£¬£¬£¬£¬£¬£¬´ÓÅÌËã»ú¸¨ÖúÒ©ÎïÉè¼Æ¡¢DNA±àÂ뻯ºÏÎï¿âµ½Êý×Ö»¯ÁÙ´²ÔËÓª½â¾ö¼Æ»®µÈ²ãÃæ£¬£¬£¬£¬£¬£¬£¬£¬ÅÌËã¿ÆÑ§ÓëÉúÎïÒ½Ò©µÄ¿ç½çÑо¿ÒѾÆÕ±éÓ¦ÓÃÓÚÐÂÒ©¿ª·¢¡£¡£¡£¡£¡£¡£¡£Îâ¼ÒȨ²©Ê¿ÌåÏÖ£º¡°°Û°¿µÃ´Ó»ùÒò×éÑо¿µ½ÂѰ×ÖÊ3D½á¹¹£¬£¬£¬£¬£¬£¬£¬£¬½¨ÉèÁËÂѰ×Öʱí´ï¡¢´¿»¯¡¢ÆÊÎöµÄһվʽƽ̨£¬£¬£¬£¬£¬£¬£¬£¬ÍŽ᾵ä½á¹¹ÉúÎïѧÒÔ¼°ÅÌËã»ú¿ÆÑ§²¢ÐγÉÁËÓÐÌØÉ«µÄ¡®Ç§°ÐÍòÃ硯¿â¡¢°Ðµã+ÃçÍ·»¯ºÏÎﹹЧ¹ØÏµÊý¾Ý°ü£¬£¬£¬£¬£¬£¬£¬£¬ÎÒÃÇÏ£ÍûÍŽá¹Å°åÑо¿ºÍÇ°ÑØ¿Æ¼¼£¬£¬£¬£¬£¬£¬£¬£¬Í¨¹ý¾«×¼¹²¾§½á¹¹ÐÔÑо¿Ì½Ë÷°ÐÂѰ×ÓëÒ©Îï·Ö×ӵĶ¯Ì¬¹¹Ð§¹ØÏµ£¬£¬£¬£¬£¬£¬£¬£¬´ÓÔ´Í·Á¢Ò츳ÄÜÈ«ÇòÐÂÒ©Ñз¢¡£¡£¡£¡£¡£¡£¡£¡±
SDDAÖ´ÐÐÖ÷ϯ¡¢·Ç·²¹ú¼ÊÒ½Ò©¶Ê³¤ÂÀÇ¿²©Ê¿ÌåÏÖ£º¡°½üÆÚî¿Ïµ»ú¹¹¹«²¼µÄÐÂÕþ£¬£¬£¬£¬£¬£¬£¬£¬Ò»¶¨ÁË»úÖÆÁ¢ÒìµÄÖ÷ÒªÐÔ¡£¡£¡£¡£¡£¡£¡£ÎÒÃÇÏàПü¶àµÄÓÐʶ֮ʿ£¬£¬£¬£¬£¬£¬£¬£¬»á´Ó»ù´¡¿ÆÑ§Í»ÆÆÖÐ̽Ë÷Ô´´µÄ°Ðµã¡¢»úÖÆºÍÒ©Îï·Ö×ÓÉè¼Æ£¬£¬£¬£¬£¬£¬£¬£¬¶ø»úÖÆÁ¢ÒìµÄÔ´Í·¼´ÊǶ¥¼âѧÊõ½ç»ú¹¹ºÍ¸÷ѧ¿ÆµÄÁì¾üѧÕß¡£¡£¡£¡£¡£¡£¡£½üÆÚAIϵͳ¶ÔÂѰ×ÖʽṹչÍûµÄǰ½ø£¬£¬£¬£¬£¬£¬£¬£¬Ê¹ÂѰ×ÖʽṹÑо¿³ÉΪÉúÎïѧ¾µä¶øÈÈÃŵÄÁìÓò£¬£¬£¬£¬£¬£¬£¬£¬ÆÚ´ý¿ÆÑ§¼ÒÃÇÄܹ»´Ó¸ÃÁìÓòµÄÓ²ºËЧ¹ûÖлñµÃ¸ü¶àÁé¸Ð£¬£¬£¬£¬£¬£¬£¬£¬Íƶ¯ÐÂÒ©¿ª·¢¡¢Ô츣ȫÇò»¼Õß¡£¡£¡£¡£¡£¡£¡£¡±